Clinical Trials
Numerous clinical trials spanning Phase 1 through Phase 4 evaluate Ribavirin across completed, recruiting, terminated, and pending recruitment statuses. Spearheaded by academic institutions, military commands, and industry leaders—such as the Liverpool School of Tropical Medicine, the U.S. Army Medical Research and Development Command, Hoffmann-La Roche, and the University of Oxford—these studies primarily target viral pathogens including Hepatitis C, Lassa Fever, Crimean-Congo Hemorrhagic Fever, and COVID-19, alongside exploratory applications in follicular and mantle cell lymphomas.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07419373 | SUSPENDED | Lassa Fever |
Arisan Therapeutics, Inc. |
2026-02-14 | PHASE2 |
| NCT04283513 | SUSPENDED | Hemorrhagic Fever |
U.S. Army Medical Research and Development Command |
2022-10-31 | PHASE2 |
| NCT06488300 | RECRUITING | Respiratory Syncytial Virus; Respiratory Syncytial Virus, Human |
University of Oxford |
2024-07-25 | PHASE2 |
| NCT02583685 | COMPLETED | Chronic Hepatitis C Infection |
Humanity and Health Research Centre |
2015-05-15 | PHASE2 |
| NCT05467826 | UNKNOWN | Hepatitis C; Cirrhosis |
Peking University People's Hospital |
2022-09-01 | PHASE4 |
| NCT05940545 | UNKNOWN | CCHF |
Liverpool School of Tropical Medicine |
2023-07-12 | PHASE1; PHASE2 |
| NCT02940496 | COMPLETED | BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7 |
M.D. Anderson Cancer Center |
2016-12-09 | PHASE2 |
| NCT05940545 | Recruiting | CCHF |
Liverpool School of Tropical Medicine |
2023-07-12 | Phase 1|Phase 2 |
| NCT05616598 | COMPLETED | Male Infertility; HCV |
Benha University |
2022-03-01 | PHASE2; PHASE3 |
| NCT04907682 | COMPLETED | Lassa Fever |
Bernhard Nocht Institute for Tropical Medicine |
2021-07-30 | PHASE2 |
| NCT01268579 | COMPLETED | HEAD & NECK Cancer |
Memorial Sloan Kettering Cancer Center |
2010-12-28 | |
| NCT04283513 | Not yet recruiting | Hemorrhagic Fever |
U.S. Army Medical Research and Development Command |
2022-10-31 | Phase 2 |
| NCT04664010 | COMPLETED | COVID-19 |
Xi'an International Medical Center Hospital |
2020-02-06 | |
| NCT04774107 | COMPLETED | Hepatitis C, Chronic |
PharmaEssentia |
2020-11-26 | PHASE1 |
| NCT04494399 | UNKNOWN | Covid19 |
The University of Hong Kong |
2020-07-29 | PHASE2 |
| NCT03759782 | UNKNOWN | Hepatitis B, Chronic |
Ottawa Hospital Research Institute |
2019-01-10 | PHASE3 |
| NCT02109744 | COMPLETED | Acute Myelogenous Leukemia |
University of Rochester |
2014-03 | PHASE1; PHASE2 |
| NCT04828564 | UNKNOWN | SARS-CoV2; COVID-19 |
The Scientific and Technological Research Council of Turkey |
2021-04 | PHASE2; PHASE3 |
| NCT04551768 | COMPLETED | COVID19 |
Bausch Health Americas, Inc. |
2021-02-10 | PHASE1 |
| NCT04546802 | WITHDRAWN | Hepatocellular Carcinoma; Hepatoma; Liver Cell Carcinoma; Hepatitis C |
Bayside Health |
2019-09 | PHASE3 |
| NCT02219490 | COMPLETED | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 |
AbbVie |
2014-10-30 | PHASE3 |
| NCT04605588 | TERMINATED | SARS-CoV Infection; Covid19 |
Rutgers, The State University of New Jersey |
2020-12-02 | PHASE2 |
| NCT03760666 | TERMINATED | Acute Myeloid Leukemia |
Clear Creek Bio, Inc. |
2018-12-20 | PHASE1; PHASE2 |
| NCT03026023 | WITHDRAWN | Cardiac Transplant Disorder; Hepatitis C |
Raymond T. Chung, MD |
2018-08-01 | PHASE4 |
| NCT03537196 | COMPLETED | Hepatitis C; Drug Use; Viral Hepatitis C |
ANRS, Emerging Infectious Diseases |
2018-11-13 | PHASE4 |
| NCT05532306 | COMPLETED | Healthy Subjects |
Future University in Egypt |
2020-10-11 | PHASE1 |
| NCT04155515 | COMPLETED | Chronic Hepatics C Virus (HCV) Genotype 1; Non-Cirrhotic; Cirrhosis; Treatment naïve |
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. |
2019-06-13 | PHASE3 |
| NCT03512210 | COMPLETED | Hepatitis C; HIV-1-infection; Liver Diseases |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2018-10-22 | PHASE4 |
| NCT03797066 | TERMINATED | Hepatitis C, Chronic |
King's College Hospital NHS Trust |
2019-03-23 | PHASE4 |
| NCT04335123 | Completed | COVID-19 |
University of Kansas Medical Center |
2020-04-04 | Phase 1 |
| NCT01502072 | COMPLETED | Bone Marrow Transplant Infection; Infection in Marrow Transplant Recipients; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Pneumonia; Cancer; Acute Leukemia |
M.D. Anderson Cancer Center |
2011-12-28 | PHASE2 |
| NCT01380938 | COMPLETED | Chronic Hepatitis |
Casa Sollievo della Sofferenza IRCCS |
2018-12-01 | PHASE3 |
| NCT04457050 | COMPLETED | Insulin Resistance; Hepatitis C |
Alexandria University |
2017-10-30 | PHASE4 |
| NCT04285034 | Completed | Lassa Fever |
University of Oxford |
2019-11-26 | -- |
| NCT03889106 | Terminated | Lassa Fever |
University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England |
2019-03-01 | -- |
| NCT03549832 | COMPLETED | HCV Coinfection |
Assiut University |
2018-01-01 | |
| NCT03362814 | COMPLETED | HCV |
Ascletis Pharmaceuticals Co., Ltd. |
2017-07-01 | PHASE2; PHASE3 |
| NCT03061032 | UNKNOWN | Hepatitis C |
Iran Hepatitis Network |
2017-03 | PHASE3 |
| NCT02992457 | COMPLETED | Hepatitis C |
Tanta University |
2015-01 | PHASE4 |
| NCT03266601 | COMPLETED | Herpangina |
Children's Hospital of Fudan University |
2016-06-01 | PHASE4 |
| NCT02994056 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2017-01-23 | PHASE2 |
| NCT03585725 | Terminated | Follicular Lymphoma|Mantle Cell Lymphoma |
Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center |
2018-09-26 | Early Phase 1 |
| NCT03499639 | COMPLETED | End-stage Renal Disease; HCV Coinfection |
Assiut University |
2018-05-01 | PHASE4 |
| NCT02249182 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2014-11-05 | PHASE2 |
| NCT02760355 | COMPLETED | Insulin Resistance |
University Hospital, Geneva |
2016-03 | |
| NCT02194998 | TERMINATED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-09-16 | PHASE2 |
| NCT02328651 | COMPLETED | Handfoot-mouth Disease |
Children's Hospital of Fudan University |
2014-10 | PHASE4 |
| NCT03004625 | COMPLETED | Hepatitis C |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2016-11 | PHASE3 |
| NCT02785666 | COMPLETED | Hepatitis C; HIV |
University of Zurich |
2016-06 | PHASE3 |
| NCT02646111 | UNKNOWN | Hepatitis C |
Tel-Aviv Sourasky Medical Center |
2016-01 | PHASE3 |
| NCT02804386 | COMPLETED | Hepatitis C, Chronic |
PharmEvo Pvt Ltd |
2016-06 | PHASE4 |
| NCT02956629 | TERMINATED | Hepatitis C |
Merck Sharp & Dohme LLC |
2016-11-16 | PHASE2 |
| NCT02771405 | COMPLETED | Hepatitis C, Chronic; Hepatocellular Carcinoma |
National Hepatology & Tropical Medicine Research Institute |
2016-03 | PHASE3 |
| NCT01721525 | COMPLETED | Head and Neck Cancer; Squamous Cell Cancer |
Memorial Sloan Kettering Cancer Center |
2012-11 | PHASE1 |
| NCT04378608 | COMPLETED | Hepatitis C Virus Infection |
Beni-Suef University |
2017-01-05 | PHASE1; PHASE2 |
| NCT02716428 | COMPLETED | Hepatitis C Viral Infection; Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1 |
Trek Therapeutics, PBC |
2016-05 | PHASE2 |
| NCT02705534 | COMPLETED | Hepatitis C; Cirrhosis |
Tehran University of Medical Sciences |
2016-09 | PHASE3 |
| NCT02293941 | TERMINATED | Chronic Hepatitis C |
TaiwanJ Pharmaceuticals Co., Ltd |
2014-05 | PHASE2 |
| NCT02304159 | COMPLETED | Hepatitis C; Cirrhosis |
Tarek I. Hassanein, M.D., FACP, FAG, AGAF |
2015-01 | PHASE4 |
| NCT03250910 | COMPLETED | Hepatitis C Virus Infection, Response to Therapy of; Human Immunodeficiency Virus |
National Taiwan University Hospital |
2016-08-01 | PHASE4 |
| NCT02822794 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2016-07-25 | PHASE3 |
| NCT02890719 | WITHDRAWN | Liver Transplantation; Hepatitis C |
Fundacion Clinic per a la Recerca Biomédica |
2016-08-03 | PHASE3 |
| NCT02985281 | UNKNOWN | Pharmacological Action |
National Liver Institute, Egypt |
2016-12 | PHASE2; PHASE3 |
| NCT02461745 | COMPLETED | Hepatitis C, Chronic |
Kaiser Permanente |
2015-06 | PHASE4 |
| NCT03453346 | COMPLETED | Hepatitis C, Chronic; Hepatitis C Virus Infection, Response to Therapy of |
Kawin Technology Share-holding Co., Ltd. |
2016-08-05 | |
| NCT02128217 | COMPLETED | HIV-1 Infection; Hepatitis |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2014-05-30 | PHASE1 |
| NCT02160080 | UNKNOWN | Late Complication From Liver Transplant |
Hu Tsung-Hui |
2014-01 | PHASE3 |
| NCT02734173 | COMPLETED | Hepatitis C |
Ottawa Hospital Research Institute |
2015-07 | PHASE4 |
| NCT02605304 | TERMINATED | HIV-1 Infection; Hepatitis C |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2016-02-17 | PHASE2 |
| NCT02613403 | TERMINATED | Hepatitis; Hepatitis C; Digestive System Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Liver Diseases; RNA Virus Infections; Virus Diseases |
Merck Sharp & Dohme LLC |
2015-12-10 | PHASE2 |
| NCT02647632 | COMPLETED | Hepatitis C |
ANRS, Emerging Infectious Diseases |
2016-01 | PHASE2 |
| NCT02207088 | COMPLETED | Chronic Hepatitis C; Hepatitis C Virus; Compensated Cirrhosis; Severe Renal Impairment; End-stage Renal Disease |
AbbVie |
2014-09-23 | PHASE3 |
| NCT02593162 | COMPLETED | Hepatitis C Viral Infection; Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 4 |
Trek Therapeutics, PBC |
2015-10 | PHASE2 |
| NCT02732405 | UNKNOWN | Hepatitis C; Compensated Cirrhosis |
Istituto Clinico Humanitas |
2016-05 | PHASE3 |
| NCT02487030 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2015-09-07 | PHASE3 |
| NCT01782495 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2013-02-25 | PHASE2 |
| NCT03020004 | COMPLETED | Chronic Hepatitis C |
Ascletis Pharmaceuticals Co., Ltd. |
2016-01 | PHASE2 |
| NCT02243293 | COMPLETED | Chronic Hepatitis C; Hepatitis C Virus |
AbbVie |
2014-09-19 | PHASE2; PHASE3 |
| NCT02601573 | COMPLETED | Hepatitis C |
Merck Sharp & Dohme LLC |
2016-01-05 | PHASE2 |
| NCT02609659 | COMPLETED | Hepatitis C Virus (HCV) |
AbbVie |
2015-10-28 | PHASE3 |
| NCT02517528 | COMPLETED | Chronic Hepatitis C Virus (HCV) |
AbbVie |
2015-07-20 | PHASE3 |
| NCT02021643 | COMPLETED | Chronic HCV Infection |
Gilead Sciences |
2013-12-10 | PHASE3 |
| NCT02265237 | COMPLETED | Hepatitis C Virus |
AbbVie |
2014-10-28 | PHASE3 |
| NCT01939197 | COMPLETED | Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhotics |
AbbVie |
2013-08-30 | PHASE2; PHASE3 |
| NCT02455167 | TERMINATED | Hepatitis C |
University of Colorado, Denver |
2015-05 | PHASE3 |
| NCT02442271 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2015-04-27 | PHASE3 |
| NCT02300103 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2014-12-01 | PHASE2 |
| NCT04385407 | COMPLETED | Chronic Hepatitis C Virus Infection |
Beni-Suef University |
2015-04 | PHASE2 |
| NCT01858961 | WITHDRAWN | Hepatitis C, Chronic |
Boehringer Ingelheim |
2013-05 | PHASE3 |
| NCT01838772 | COMPLETED | Hepatitis C; HIV |
amfAR, The Foundation for AIDS Research |
2013-12 | PHASE4 |
| NCT02204475 | WITHDRAWN | Hepatitis C |
Merck Sharp & Dohme LLC |
2014-11 | PHASE3 |
| NCT02551861 | WITHDRAWN | Hepatitis C |
Bristol-Myers Squibb |
2015-12 | PHASE2 |
| NCT03547895 | COMPLETED | Decompensated Cirrhosis |
Zagazig University |
2015-06-01 | |
| NCT01227967 | COMPLETED | Influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
2010-09 | PHASE2 |
| NCT02120274 | TERMINATED | RNA Virus Infections; Flaviviridae Infections; Hepatitis C; Hepatitis C, Chronic |
Federal University of São Paulo |
2014-03 | PHASE4 |
| NCT02596880 | COMPLETED | Hepatitis C; Cirrhosis |
Tehran University of Medical Sciences |
2015-09 | PHASE3 |
| NCT02493855 | COMPLETED | Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1a |
AbbVie |
2015-06 | PHASE2 |
| NCT02536313 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2015-07-29 | PHASE2 |
| NCT03069001 | COMPLETED | HCV |
Ain Shams University |
2015-06 | PHASE4 |
| NCT00680173 | COMPLETED | Chronic Hepatitis C |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2006-08 | PHASE4 |
| NCT02377856 | COMPLETED | Acute Hepatitis C |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2007-06 | PHASE4 |
| NCT02243280 | COMPLETED | Chronic Hepatitis C; Hepatitis C Virus; HCV |
AbbVie |
2014-08 | PHASE2 |
| NCT02006745 | COMPLETED | HIV |
St Stephens Aids Trust |
2014-01 | PHASE3 |
| NCT02371408 | UNKNOWN | Chronic Hepatitis C |
Pharco Pharmaceuticals |
2015-01 | PHASE2; PHASE3 |
| NCT02702739 | COMPLETED | Liver Cirrhosis |
Azienda Ospedaliera San Camillo Forlanini |
2015-01 | PHASE4 |
| NCT02216422 | COMPLETED | Chronic Hepatitis C Virus (HCV) Infection |
AbbVie |
2014-09 | PHASE3 |
| NCT02399345 | COMPLETED | Chronic Hepatitis C Virus (HCV Infection Genotype 1) |
AbbVie |
2015-03 | PHASE3 |
| NCT02309450 | WITHDRAWN | Hepatitis C Virus Genotype 4 Infection |
ANRS, Emerging Infectious Diseases |
2014-12 | PHASE2 |
| NCT02319031 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2015-02 | PHASE3 |
| NCT02201953 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2014-07 | PHASE3 |
| NCT02103439 | COMPLETED | Hepatitis; Hepatitis C; Hepatitis C/ Human Immunodeficiency Virus Coinfection |
Biocad |
2013-06-06 | PHASE3 |
| NCT01097395 | COMPLETED | Hepatitis C Virus |
University of Colorado, Denver |
2010-02 | PHASE4 |
| NCT02120300 | COMPLETED | Chronic HCV Infection |
Gilead Sciences |
2014-04 | PHASE2 |
| NCT01912495 | COMPLETED | Hepatitis C; Human Immunodeficiency Virus |
Erasmus Medical Center |
2013-08 | PHASE2 |
| NCT01846832 | COMPLETED | Hepatitis C, Chronic; Infection |
Janssen-Cilag International NV |
2013-09 | PHASE3 |
| NCT01390844 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2011-10-21 | PHASE3 |
| NCT02690103 | COMPLETED | Hepatitis C, Chronic |
Cairo University |
2012-07 | PHASE2 |
| NCT02128542 | COMPLETED | Hepatitis C Virus Infection |
Gilead Sciences |
2014-06 | PHASE4 |
| NCT01925183 | COMPLETED | Hepatitis C, Chronic; HIV |
Markus Peck-Radosavljevic |
2013-08 | PHASE4 |
| NCT01364090 | COMPLETED | Hepatitis C, Chronic |
Kirby Institute |
2012-06 | PHASE4 |
| NCT01544920 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2012-05-30 | PHASE3 |
| NCT02105454 | COMPLETED | Hepatitis C Virus |
Merck Sharp & Dohme LLC |
2014-05-23 | PHASE2 |
| NCT02010255 | COMPLETED | Chronic HCV Infection |
Gilead Sciences |
2014-01 | PHASE2 |
| NCT01938625 | COMPLETED | Hepatitis C, Chronic |
Janssen R&D Ireland |
2013-12-12 | PHASE2 |
| NCT02023112 | COMPLETED | Hepatitis C Virus |
AbbVie |
2014-01 | PHASE3 |
| NCT01482767 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2012-04 | PHASE3 |
| NCT02094443 | COMPLETED | Hepatitis C; Liver Disease |
Debiopharm International SA |
2014-03 | PHASE2 |
| NCT01852604 | COMPLETED | Chronic Hepatitis C Virus |
Merck Sharp & Dohme LLC |
2013-03 | PHASE2 |
| NCT02105701 | COMPLETED | Hepatitis C Infection |
Merck Sharp & Dohme LLC |
2014-06-05 | PHASE3 |
| NCT01718301 | TERMINATED | Hepatitis C; HIV Infections; COINFECTION |
Anna Cruceta |
2013-03-10 | PHASE3 |
| NCT01970904 | COMPLETED | Hepatitis C; Liver Disease |
Debiopharm International SA |
2013-10 | |
| NCT02008214 | UNKNOWN | Hepacivirus; HIV Infections |
Centro Universitario de Ciencias de la Salud, Mexico |
2013-12 | PHASE4 |
| NCT01717326 | COMPLETED | Hepatitis C |
Merck Sharp & Dohme LLC |
2013-02-07 | PHASE2 |
| NCT02063607 | COMPLETED | Hepatitis C |
Nanogen Pharmaceutical Biotechnology Joint Stock Company |
2013-12 | PHASE1 |
| NCT01749150 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2013-04 | PHASE2 |
| NCT02107365 | COMPLETED | Hepatitis C Virus Genotype 4 Infection |
ANRS, Emerging Infectious Diseases |
2013-11 | PHASE2 |
| NCT01741545 | COMPLETED | Hepatitis C Virus |
Bristol-Myers Squibb |
2013-03-31 | PHASE3 |
| NCT02175966 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2014-07-28 | PHASE2 |
| NCT01606800 | TERMINATED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2013-01-01 | PHASE4 |
| NCT01872936 | UNKNOWN | Hepatitis C, Chronic |
Santaris Pharma A/S |
2013-06 | PHASE2 |
| NCT01896609 | UNKNOWN | Chronic Hepatitis c |
MinaPharm Pharmaceuticals |
2013-06 | PHASE4 |
| NCT01964742 | COMPLETED | HIV-HCV Co-infected Patients |
Assistance Publique Hopitaux De Marseille |
2013-10 | |
| NCT01854697 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie |
2013-03 | PHASE3 |
| NCT02261662 | UNKNOWN | Hepatitis C; Lichen Planus; Vasculitis; Autoimmune Diseases |
Tanta University |
2014-06 | |
| NCT00689390 | TERMINATED | Hepatitis C, Chronic; Hepacivirus |
Merck Sharp & Dohme LLC |
2007-02-20 | PHASE2; PHASE3 |
| NCT01830127 | COMPLETED | Hepatitis C, Chronic |
Boehringer Ingelheim |
2013-04 | PHASE2 |
| NCT01704521 | COMPLETED | Chronic Hepatitis C; Hemophilia |
Kenneth Sherman |
2012-12 | PHASE1 |
| NCT01724086 | COMPLETED | Chronic Hepatitis C |
Janssen R&D Ireland |
2012-10 | PHASE2 |
| NCT01754974 | COMPLETED | Hepatitis C Virus (HCV) |
Bristol-Myers Squibb |
2013-03 | PHASE3 |
| NCT01592006 | TERMINATED | Hepatitis C |
University of Chicago |
2012-04 | PHASE4 |
| NCT01428063 | COMPLETED | Hepatitis C Virus Infection |
Bristol-Myers Squibb |
2011-09 | PHASE2 |
| NCT01226771 | COMPLETED | Hepatitis C |
Göteborg University |
2010-09 | PHASE3 |
| NCT01500616 | COMPLETED | Hepatitis C, Chronic |
Janssen-Cilag International NV |
2012-06 | PHASE3 |
| NCT01965535 | COMPLETED | HCV Infection |
Gilead Sciences |
2013-10 | PHASE2 |
| NCT01725529 | COMPLETED | Hepatitis C, Chronic |
Janssen R&D Ireland |
2012-11 | PHASE3 |
| NCT01648140 | COMPLETED | Hepatitis C, Chronic |
GlaxoSmithKline |
2012-08-01 | PHASE2 |
| NCT03090035 | COMPLETED | Hepatitis C; Hepatitis C Relapse |
Sheikh Zayed Medical College |
2014-01-01 | PHASE3 |
| NCT01790100 | COMPLETED | Chronic Hepatitis C |
Alios Biopharma Inc. |
2013-02-28 | PHASE2 |
| NCT01975675 | COMPLETED | Chronic HCV Infection |
Gilead Sciences |
2013-10 | PHASE3 |
| NCT01263860 | COMPLETED | Chronic Hepatitis C |
Third Affiliated Hospital, Sun Yat-Sen University |
2010-12 | PHASE3 |
| NCT01330316 | COMPLETED | Hepatitis C |
Boehringer Ingelheim |
2011-07 | PHASE3 |
| NCT01685203 | COMPLETED | Hepatitis C, Chronic |
AbbVie (prior sponsor, Abbott) |
2012-08 | PHASE2 |
| NCT01559844 | COMPLETED | Hepatitis C; Hepatocellular Carcinoma |
Gilead Sciences |
2012-03 | PHASE2 |
| NCT01467492 | TERMINATED | Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2012-01 | PHASE4 |
| NCT01335529 | COMPLETED | HCV Coinfection; HIV-1 Infection |
ANRS, Emerging Infectious Diseases |
2011-05 | PHASE2 |
| NCT01859962 | COMPLETED | Chronic Hepatitis C |
Presidio Pharmaceuticals, Inc. |
2013-05 | PHASE2 |
| NCT01441804 | UNKNOWN | Chronic Hepatitis C |
Third Affiliated Hospital, Sun Yat-Sen University |
2011-05 | PHASE3 |
| NCT01795911 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2013-03 | PHASE2 |
| NCT01571583 | COMPLETED | Chronic Hepatitis C Virus (HCV) Infection |
Janssen-Cilag International NV |
2012-02 | PHASE3 |
| NCT01297270 | COMPLETED | Hepatitis C |
Boehringer Ingelheim |
2011-04 | PHASE3 |
| NCT01455090 | COMPLETED | Chronic Hepatitis C |
Bristol-Myers Squibb |
2011-11-30 | PHASE2 |
| NCT01910636 | COMPLETED | Hepatitis C |
Gilead Sciences |
2013-02 | PHASE3 |
| NCT01579019 | WITHDRAWN | Hepatitis C, Chronic |
Hoffmann-La Roche |
2012-07 | PHASE2 |
| NCT01447394 | WITHDRAWN | Hepatitis C Virus (HCV) |
Bristol-Myers Squibb |
2012-03 | PHASE3 |
| NCT01343888 | COMPLETED | Hepatitis C |
Boehringer Ingelheim |
2011-04 | PHASE3 |
| NCT01467479 | TERMINATED | Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2011-12 | PHASE3 |
| NCT01355289 | COMPLETED | Thrombocytopenia |
Eisai Inc. |
2011-11 | PHASE2 |
| NCT01727934 | UNKNOWN | Hepatitis C |
Santaris Pharma A/S |
2012-11 | PHASE2 |
| NCT01704755 | COMPLETED | Chronic Hepatitis C Infection; Compensated Cirrhosis |
AbbVie (prior sponsor, Abbott) |
2012-10 | PHASE3 |
| NCT01567540 | TERMINATED | Hepatitis C |
Institut National de la Santé Et de la Recherche Médicale, France |
2013-03 | PHASE1 |
| NCT01585324 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2012-01 | PHASE4 |
| NCT01674725 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-08 | PHASE3 |
| NCT01716156 | COMPLETED | Hepatitis C |
Merck Sharp & Dohme LLC |
2013-01-18 | PHASE2 |
| NCT01457937 | UNKNOWN | Chronic Hepatitis C; Menopause |
University of Modena and Reggio Emilia |
2011-11 | PHASE3 |
| NCT01718145 | COMPLETED | Hepatitis C Virus Infection |
Bristol-Myers Squibb |
2012-11 | PHASE3 |
| NCT00887081 | UNKNOWN | Hemoglobinopathies |
Azienda Ospedaliera V. Cervello |
2009-01 | PHASE4 |
| NCT00540345 | COMPLETED | Chronic Hepatitis C |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2006-10 | PHASE4 |
| NCT01525628 | COMPLETED | Hepatitis C, Chronic |
Boehringer Ingelheim |
2012-04 | PHASE1 |
| NCT01710501 | COMPLETED | Chronic Hepatitis C (CHC) |
Merck Sharp & Dohme LLC |
2012-12-07 | PHASE2 |
| NCT01466790 | COMPLETED | Hepatitis C |
Janssen R&D Ireland |
2012-01 | PHASE2 |
| NCT01715415 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-11 | PHASE3 |
| NCT01667731 | COMPLETED | Hepatitis C; Human Immunodeficiency Virus |
Gilead Sciences |
2012-07 | PHASE3 |
| NCT01849562 | COMPLETED | Hepatitis C, Chronic |
Alexion Pharmaceuticals, Inc. |
2013-04 | PHASE2 |
| NCT01260350 | COMPLETED | Chronic Hepatitis C Infection |
Gilead Sciences |
2010-12 | PHASE2 |
| NCT01716585 | COMPLETED | Chronic Hepatitis C Infection |
AbbVie (prior sponsor, Abbott) |
2012-11 | PHASE3 |
| NCT01399619 | COMPLETED | Hepatitis C, Chronic |
Boehringer Ingelheim |
2011-09 | PHASE3 |
| NCT01389323 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2011-09 | PHASE3 |
| NCT01045278 | COMPLETED | Hepatitis C |
Region Skane |
2008-04 | PHASE4 |
| NCT01516918 | COMPLETED | Chronic Hepatitis C Virus |
Vertex Pharmaceuticals Incorporated |
2012-02 | PHASE2 |
| NCT01483742 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2012-04 | PHASE2 |
| NCT01289496 | COMPLETED | Chronic Hepatitis C |
Centre hospitalier de l'Université de Montréal (CHUM) |
2011-02 | PHASE2 |
| NCT01528735 | COMPLETED | Hepatitis C, Chronic |
Boehringer Ingelheim |
2012-02 | PHASE2 |
| NCT01377909 | TERMINATED | Chronic Hepatitis C |
Bader, Ted, M.D. |
2012-03 | PHASE1 |
| NCT01565889 | COMPLETED | Hepatitis C; HIV |
Gilead Sciences |
2012-03 | PHASE1; PHASE2 |
| NCT01726517 | COMPLETED | Chronic Hepatitis C Virus |
Gilead Sciences |
2012-10 | PHASE2 |
| NCT02069665 | COMPLETED | Pneumonia |
Liaoning University of Traditional Chinese Medicine |
2011-12 | |
| NCT01957319 | COMPLETED | Work Ability; Depression |
University of Catania |
2010-02 | PHASE3 |
| NCT01429792 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2008-09-25 | PHASE4 |
| NCT01384383 | TERMINATED | Chronic Hepatitis C |
Gilead Sciences |
2011-08 | PHASE2 |
| NCT00735969 | COMPLETED | Chronic Hepatitis C |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2008-08 | PHASE2 |
| NCT01356160 | COMPLETED | Hepatitis C, Chronic |
Gilead Sciences |
2011-07 | PHASE2 |
| NCT00662220 | TERMINATED | Chronic Hepatitis C |
Foundation for Liver Research |
2008-04 | PHASE3 |
| NCT00943761 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2009-10-23 | PHASE2 |
| NCT00938860 | COMPLETED | Hepatitis C; Liver Transplantation |
Novartis Pharmaceuticals |
2009-09 | PHASE4 |
| NCT01446250 | TERMINATED | Hepatitis C |
Debiopharm International SA |
2011-12 | PHASE3 |
| NCT01497834 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2012-01 | PHASE3 |
| NCT02113631 | COMPLETED | Hepatitis C, Chronic; Cirrhosis |
Louis Stokes VA Medical Center |
2011-09 | |
| NCT01371604 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2011-07 | PHASE2 |
| NCT01464827 | COMPLETED | Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1 |
AbbVie (prior sponsor, Abbott) |
2011-10 | PHASE2 |
| NCT01371578 | COMPLETED | Hepatitis C, Chronic |
Gilead Sciences |
2011-07 | PHASE2 |
| NCT01405937 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2011-08-29 | PHASE3 |
| NCT01358864 | COMPLETED | Hepatitis C, Chronic |
Boehringer Ingelheim |
2011-06 | PHASE3 |
| NCT01281839 | COMPLETED | Hepatitis C |
Janssen R&D Ireland |
2011-02 | PHASE3 |
| NCT00323804 | COMPLETED | Hepatitis C, Chronic; Liver Fibrosis |
ANRS, Emerging Infectious Diseases |
2006-05 | PHASE2; PHASE3 |
| NCT01359644 | COMPLETED | Chronic Hepatitis C |
Bristol-Myers Squibb |
2011-06 | PHASE2 |
| NCT01434498 | COMPLETED | Chronic Genotype 1a or 1b HCV Infection |
Gilead Sciences |
2011-09 | PHASE2 |
| NCT01271790 | COMPLETED | Hepatitis C, Chronic |
Gilead Sciences |
2010-10 | PHASE2 |
| NCT01435226 | COMPLETED | Hepatitis C, Chronic |
Gilead Sciences |
2011-09 | PHASE2 |
| NCT00761735 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2007-07 | PHASE3 |
| NCT00910624 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2009-06-22 | PHASE3 |
| NCT00484328 | COMPLETED | Hepatitis C |
Maastricht University Medical Center |
2007-07 | PHASE4 |
| NCT00977054 | TERMINATED | Hepatitis C |
National Taiwan University Hospital |
2009-09 | PHASE4 |
| NCT00840489 | TERMINATED | Chronic Hepatitis C |
Hospital Universitario Ramon y Cajal |
2009-01 | PHASE2 |
| NCT00892697 | COMPLETED | Hepatitis C |
Weill Medical College of Cornell University |
2009-05 | PHASE2 |
| NCT01447420 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2011-02 | PHASE4 |
| NCT00788918 | COMPLETED | Hepatitis C, Chronic; Cognition Disorders; Fatigue Syndrome, Chronic; Major Depressive Disorder |
Aarhus University Hospital |
2008-11 | |
| NCT01542788 | COMPLETED | Chronic Hepatitis C |
Gilead Sciences |
2012-03 | PHASE3 |
| NCT00606086 | COMPLETED | Genotype 1 Chronic Hepatitis C |
GlobeImmune |
2007-12 | PHASE2 |
| NCT01278134 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2011-02 | PHASE2 |
| NCT01012895 | COMPLETED | Chronic Hepatitis C |
Bristol-Myers Squibb |
2009-12 | PHASE2 |
| NCT01055821 | COMPLETED | Chronic Hepatitis C Infection |
Transgene |
2010-05 | PHASE2 |
| NCT02601976 | COMPLETED | Hepatitis C |
Getz Pharma |
2010-08 | PHASE4 |
| NCT00911963 | COMPLETED | Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2009-04 | PHASE1; PHASE2 |
| NCT01241760 | COMPLETED | Genotype 1 Chronic Hepatitis C; Treatment Naive |
Janssen Infectious Diseases BVBA |
2010-12 | PHASE3 |
| NCT01329978 | COMPLETED | Hepatitis C, Chronic |
Gilead Sciences |
2011-03 | PHASE2 |
| NCT00927290 | TERMINATED | Chronic Hepatitis C; Insulin Resistance |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-12-03 | PHASE3 |
| NCT01740089 | COMPLETED | Hepatitis; Hepatitis C |
Biocad |
2011-11 | PHASE2; PHASE3 |
| NCT00919633 | COMPLETED | Hepatitis C |
Medtronic Corporate Technologies and New Ventures |
2009-06 | PHASE2 |
| NCT00901524 | COMPLETED | Hepatitis |
ANRS, Emerging Infectious Diseases |
2009-06 | PHASE2 |
| NCT01056172 | UNKNOWN | Chronic Hepatitis C |
Pusan National University Yangsan Hospital |
2010-01 | PHASE4 |
| NCT01170962 | COMPLETED | Hepatitis C Virus |
Bristol-Myers Squibb |
2010-08 | PHASE2 |
| NCT01440595 | TERMINATED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2011-11-28 | PHASE2 |
| NCT01445795 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2011-09 | PHASE1; PHASE2 |
| NCT01500772 | TERMINATED | Hepatitis C |
Debiopharm International SA |
2012-03 | PHASE3 |
| NCT01215643 | COMPLETED | Hepatitis C; Chronic Pain |
Debiopharm International SA |
2010-10 | PHASE2 |
| NCT01257204 | COMPLETED | Hepatitis C Virus |
Bristol-Myers Squibb |
2010-12 | PHASE2 |
| NCT01337375 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2011-03 | PHASE1 |
| NCT01125189 | COMPLETED | Hepatitis C Virus |
Bristol-Myers Squibb |
2010-07 | PHASE2 |
| NCT01180790 | COMPLETED | Hepatitis C |
Alexion Pharmaceuticals, Inc. |
2010-09 | PHASE2 |
| NCT00800735 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2009-04 | PHASE3 |
| NCT00317746 | COMPLETED | Depression; HIV Infections; Hepatitis C |
Marina Klein |
2006-11 | PHASE3 |
| NCT00983853 | COMPLETED | Hepatitis C; HIV Infections |
Vertex Pharmaceuticals Incorporated |
2009-10 | PHASE2 |
| NCT00869661 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2001-02 | PHASE2 |
| NCT01226446 | COMPLETED | Chronic Hepatitis C |
French National Agency for Research on AIDS and Viral Hepatitis |
2010-11 | PHASE2 |
| NCT01151397 | UNKNOWN | Chronic Hepatitis C |
Ziv Hospital |
2011-08 | |
| NCT01273948 | COMPLETED | Hepatitis C |
Peregrine Pharmaceuticals |
2011-01 | PHASE1; PHASE2 |
| NCT01272310 | UNKNOWN | Chronic Hepatitis C |
Sheba Medical Center |
2011-01 | PHASE1; PHASE2 |
| NCT00881582 | COMPLETED | Chronic Hepatitis C; Renal Transplant |
King Abdulaziz Medical City |
2009-01 | PHASE4 |
| NCT01006031 | COMPLETED | Liver Cirrhosis; Hepatitis C Virus; HIV Infection |
Sociedad Andaluza de Enfermedades Infecciosas |
2009-10 | PHASE2; PHASE3 |
| NCT01909557 | COMPLETED | Quality of Life; Daily Activity; Fatigue |
University of Catania |
2010-01 | PHASE3 |
| NCT01596517 | COMPLETED | Chronic Hepatitis C |
Asan Medical Center |
2003-06 | PHASE4 |
| NCT01194037 | COMPLETED | Chronic Hepatitis C Infection; Genotype 1 |
HanAll BioPharma Co., Ltd. |
2011-06-23 | PHASE1; PHASE2 |
| NCT01023035 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2009-12-07 | PHASE3 |
| NCT01185028 | COMPLETED | Hepatitis C Infection; HIV Infection |
National Institutes of Health Clinical Center (CC) |
2010-08 | PHASE1; PHASE2 |
| NCT01615393 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-06 | PHASE1 |
| NCT00830609 | COMPLETED | Chronic Hepatitis C |
Dr. Conrado Fernandez |
2008-11 | PHASE4 |
| NCT01273064 | TERMINATED | Hepatitis C |
Conatus Pharmaceuticals Inc. |
2011-01 | PHASE2 |
| NCT01853254 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2003-09 | PHASE3 |
| NCT00947349 | COMPLETED | Hepatitis C; Pharmacokinetics |
Boehringer Ingelheim |
2009-07 | PHASE2 |
| NCT01415141 | WITHDRAWN | Hepatitis C |
University of Vermont |
2011-07 | PHASE4 |
| NCT01074008 | COMPLETED | Hepatitis C; HCV; Chronic Hepatitis C Infection; Hepatitis C Genotype 1 |
AbbVie (prior sponsor, Abbott) |
2010-03 | PHASE2 |
| NCT00984620 | COMPLETED | Hepatitis C |
Boehringer Ingelheim |
2009-09 | PHASE2 |
| NCT01188772 | COMPLETED | Hepatitis C Virus |
Gilead Sciences |
2010-08 | PHASE2 |
| NCT00944684 | COMPLETED | Chronic Hepatitis C |
University of Bern |
2007-11 | PHASE2 |
| NCT00968357 | COMPLETED | Chronic Hepatitis C |
SciClone Pharmaceuticals |
2009-09 | PHASE2 |
| NCT00686517 | COMPLETED | Hepatitis C |
Merck Sharp & Dohme LLC |
2003-12 | PHASE3 |
| NCT01058512 | COMPLETED | Hepatitis C |
Cellectar Biosciences, Inc. |
2010-03 | PHASE2 |
| NCT00759200 | COMPLETED | Chronic Hepatitis C |
Novartis |
2008-10 | PHASE2 |
| NCT00686777 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2008-01 | PHASE4 |
| NCT01142700 | WITHDRAWN | Chronic Hepatitis C Virus Genotype 1 |
Bristol-Myers Squibb |
2010-07 | PHASE2 |
| NCT00845676 | COMPLETED | Hepatitis C; Human Immunodeficiency Virus; HIV Infections |
University of California, San Francisco |
2008-03 | PHASE4 |
| NCT01001754 | UNKNOWN | Hepatitis C, Chronic |
ZymoGenetics |
2010-05 | PHASE2 |
| NCT00863239 | COMPLETED | Hepatitis C, Chronic |
Biolex Therapeutics, Inc. |
2009-03 | PHASE2 |
| NCT00991289 | COMPLETED | HIV Infection; Hepatitis C Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
2010-01 | PHASE2 |
| NCT00814606 | WITHDRAWN | Hepatitis C; Hepatitis C Virus |
University of Chicago |
2010-02 | PHASE2 |
| NCT00687219 | COMPLETED | Hepatitis C, Chronic; Liver Cirrhosis |
Merck Sharp & Dohme LLC |
2007-06 | PHASE3 |
| NCT01072695 | COMPLETED | HCV Infection |
Gilead Sciences |
2010-02 | PHASE2 |
| NCT00780910 | COMPLETED | Chronic Hepatitis C |
Tanabe Pharma Corporation |
2008-11 | PHASE3 |
| NCT00412334 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2007-01 | PHASE4 |
| NCT00854802 | COMPLETED | Chronic Hepatitis C |
Debiopharm International SA |
2009-01 | |
| NCT00437476 | UNKNOWN | HIV Infections; Hepatitis C |
IRCCS San Raffaele |
2007-02 | PHASE3 |
| NCT00703118 | COMPLETED | Hepatitis C, Chronic |
Tibotec BVBA |
2008-10 | PHASE3 |
| NCT01011166 | COMPLETED | Chronic Hepatitis C Infection |
Merck Sharp & Dohme LLC |
2009-11 | PHASE2 |
| NCT00437684 | UNKNOWN | HIV Infections; Hepatitis C |
IRCCS San Raffaele |
2007-02 | PHASE3 |
| NCT00880763 | COMPLETED | Hepatitis C |
Merck Sharp & Dohme LLC |
2009-04-20 | PHASE2 |
| NCT00624325 | COMPLETED | Chronic Hepatitis C |
Foundation for Liver Research |
2007-07 | PHASE2; PHASE3 |
| NCT00028093 | COMPLETED | Chronic Hepatitis C |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2001-12 | PHASE4 |
| NCT00192569 | COMPLETED | Hepatitis C |
Kirby Institute |
2004-07 | PHASE4 |
| NCT00925990 | COMPLETED | Hepatitis C |
Conatus Pharmaceuticals Inc. |
2009-06 | PHASE2 |
| NCT00979251 | COMPLETED | Influenza |
Adamas Pharmaceuticals, Inc. |
2009-09 | PHASE2 |
| NCT00637923 | COMPLETED | Chronic Hepatitis C |
Romark Laboratories L.C. |
2008-03 | PHASE2 |
| NCT00978497 | COMPLETED | HCV Infection |
Hoffmann-La Roche |
2009-09 | PHASE2 |
| NCT00708500 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2008-08 | PHASE3 |
| NCT00571714 | WITHDRAWN | Chronic Hepatitis C |
University of Nebraska |
2008-04-01 | |
| NCT00720434 | COMPLETED | Hepatitis C |
Pfizer |
2008-08 | PHASE2 |
| NCT00559091 | COMPLETED | Acute Myelocytic Leukemia |
Jewish General Hospital |
2007-04 | PHASE2 |
| NCT00535847 | COMPLETED | Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2007-10 | PHASE2 |
| NCT00239733 | TERMINATED | Thrombocytopenia; Hepatitis C; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-03 | PHASE4 |
| NCT00207402 | COMPLETED | Hepatitis C |
Brooke Army Medical Center |
2005-10 | PHASE4 |
| NCT00207363 | COMPLETED | Hepatitis C |
Brooke Army Medical Center |
2002-02 | PHASE4 |
| NCT00056862 | COMPLETED | Hepatitis C |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2003-03 | PHASE4 |
| NCT00351403 | COMPLETED | Hepatitis C, Chronic |
FGK Clinical Research GmbH |
2006-07 | PHASE4 |
| NCT00580801 | COMPLETED | Hepatitis C |
Tibotec BVBA |
2008-01 | PHASE2 |
| NCT00641654 | TERMINATED | Chronic Hepatitis C |
Göteborg University |
2007-01 | PHASE4 |
| NCT01195181 | COMPLETED | Hepatitis C Virus; Chronic Liver Disease; Viral Hepatitis; Therapeutic Uses; Antiviral Agents |
Azienda Ospedaliera di Padova |
2005-09 | PHASE4 |
| NCT00834860 | UNKNOWN | Chronic Hepatitis C; Hepatocellular Carcinoma |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2007-01 | PHASE4 |
| NCT00823862 | COMPLETED | Chronic Hepatitis C |
Dynavax Technologies Corporation |
2008-10 | PHASE1 |
| NCT01296971 | WITHDRAWN | Hepatitis C, Chronic |
Hoffmann-La Roche |
2009-12 | PHASE3 |
| NCT00940420 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2002-10 | PHASE4 |
| NCT00759109 | COMPLETED | Carcinoma, Hepatocellular |
Merck Sharp & Dohme LLC |
2002-03 | PHASE3 |
| NCT00982553 | COMPLETED | HIV Infections |
Imperial College London |
2009-09 | PHASE1 |
| NCT00423800 | TERMINATED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2006-12 | PHASE3 |
| NCT00493805 | TERMINATED | Hepatitis C, Chronic; Insulin Resistance |
Merck Sharp & Dohme LLC |
2007-04 | PHASE4 |
| NCT00565539 | COMPLETED | Hepatitis C, Chronic |
ZymoGenetics |
2007-12 | PHASE1 |
| NCT00707850 | COMPLETED | Hepatitis C; Thalassemia |
Baqiyatallah Medical Sciences University |
2007-05 | PHASE4 |
| NCT00867139 | COMPLETED | Influenza |
Fred Hutchinson Cancer Center |
2009-03 | PHASE1; PHASE2 |
| NCT00797745 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2008-11 | PHASE2 |
| NCT00378599 | COMPLETED | Liver Transplantation; Hepatitis C, Chronic; Liver Cirrhosis |
Merck Sharp & Dohme LLC |
2006-05 | PHASE3 |
| NCT00743795 | COMPLETED | HCV Infection |
Gilead Sciences |
2008-10 | PHASE2 |
| NCT00262379 | COMPLETED | Chronic Hepatitis C |
University Hospital, Angers |
2005-12 | PHASE3 |
| NCT00856804 | UNKNOWN | Hepatitis C |
Valme University Hospital |
2009-03 | PHASE2 |
| NCT02762383 | TERMINATED | HIV/HCV Coinfection |
Hoffmann-La Roche |
2005-03 | PHASE3 |
| NCT00502099 | COMPLETED | Hepatitis C |
Amr Hafez |
2006-01 | PHASE4 |
| NCT00629824 | COMPLETED | Chronic Hepatitis C |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2007-02 | PHASE4 |
| NCT00353418 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2006-06 | PHASE4 |
| NCT00356486 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2005-10 | PHASE4 |
| NCT00192647 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2004-08 | PHASE4 |
| NCT00402428 | COMPLETED | Chronic Hepatitis C |
Human Genome Sciences Inc. |
2006-12 | PHASE3 |
| NCT00800748 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2006-02-01 | PHASE4 |
| NCT00500578 | COMPLETED | Hematological Malignancies |
M.D. Anderson Cancer Center |
2003-02 | PHASE4 |
| NCT00209898 | TERMINATED | Chronic Hepatitis C |
Haukeland University Hospital |
2003-08 | PHASE4 |
| NCT00420784 | COMPLETED | Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2007-02 | PHASE2 |
| NCT00332176 | UNKNOWN | Chronic Hepatitis C |
BioWest Therapeutics Inc |
2006-06 | PHASE2 |
| NCT00148837 | COMPLETED | Hepatitis C, Chronic; Fibrosis |
French National Agency for Research on AIDS and Viral Hepatitis |
2004-09 | PHASE2 |
| NCT00085917 | COMPLETED | Hepatitis C; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-06 | PHASE2 |
| NCT02259855 | COMPLETED | Hepatic Insufficiency |
Boehringer Ingelheim |
2006-01-01 | PHASE1 |
| NCT00411385 | COMPLETED | Chronic Hepatitis C |
Human Genome Sciences Inc. |
2007-02 | PHASE3 |
| NCT00421434 | COMPLETED | Chronic Hepatitis C |
Romark Laboratories L.C. |
2006-06 | PHASE2; PHASE3 |
| NCT00687544 | TERMINATED | Hepatitis C, Chronic; Hepacivirus; HIV Infections |
Merck Sharp & Dohme LLC |
2005-12 | PHASE4 |
| NCT00100659 | COMPLETED | Chronic Hepatitis C |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2004-12 | PHASE3 |
| NCT01258101 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2003-05 | PHASE4 |
| NCT00202839 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2005-03 | PHASE4 |
| NCT00211692 | COMPLETED | Chronic Hepatitis C |
Minneapolis Veterans Affairs Medical Center |
2005-07 | PHASE3 |
| NCT00491179 | COMPLETED | Chronic Hepatitis C; Hemodialysis |
National Taiwan University Hospital |
2006-06 | PHASE4 |
| NCT00495131 | COMPLETED | Hepatitis C, Chronic |
National Taiwan University Hospital |
2006-06 | PHASE4 |
| NCT00687999 | COMPLETED | Chronic Hepatitis C; Insulin Resistance |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2005-12 | |
| NCT00441584 | TERMINATED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2005-07 | PHASE3 |
| NCT00133276 | COMPLETED | Hepatitis C |
Foundation for Liver Research |
2005-08 | PHASE2; PHASE3 |
| NCT01178996 | COMPLETED | Chronic Hepatitis C |
sigma-tau i.f.r. S.p.A. |
2004-12 | PHASE3 |
| NCT00372385 | COMPLETED | Chronic Hepatitis C |
Vertex Pharmaceuticals Incorporated |
2006-08 | PHASE2 |
| NCT00114361 | COMPLETED | Hepatitis B |
Foundation for Liver Research |
2005-03 | PHASE3 |
| NCT00265395 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2004-12 | PHASE3 |
| NCT02761629 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2005-04 | PHASE4 |
| NCT00087646 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2003-09 | PHASE4 |
| NCT00446134 | COMPLETED | Chronic Hepatitis C |
Bausch Health Americas, Inc. |
2007-03 | PHASE2 |
| NCT00167557 | WITHDRAWN | Hepatitis C |
The University of Texas Health Science Center, Houston |
2005-01 | PHASE4 |
| NCT00724620 | COMPLETED | Hepatitis C, Chronic |
Schering-Plough |
2005-06 | PHASE4 |
| NCT00433069 | COMPLETED | Chronic Hepatitis C |
University Hospital, Geneva |
2007-01 | PHASE2 |
| NCT00502970 | COMPLETED | Hepatitis C; Chronic Disease; Treatment |
Aga Khan University |
2004-05 | PHASE4 |
| NCT00081770 | COMPLETED | Hepatitis C, Chronic |
Merck Sharp & Dohme LLC |
2004-03 | PHASE3 |
| NCT00107653 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2004-10 | PHASE4 |
| NCT00097435 | COMPLETED | Hepatitis C |
Human Genome Sciences Inc. |
2004-10 | PHASE2 |
| NCT00277238 | COMPLETED | Hepatitis, Chronic Active |
Pfizer |
2006-02 | PHASE2 |
| NCT00275548 | COMPLETED | Liver Transplant; Hepatitis C |
Mayo Clinic |
2004-07 | PHASE4 |
| NCT00147784 | COMPLETED | Opiate Dependence; Hepatitis |
Sorlandet Hospital HF |
2006-03 | PHASE3 |
| NCT00078403 | COMPLETED | HIV Infections; Hepatitis C; Liver Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | PHASE2 |
| NCT00115908 | COMPLETED | Hepatitis C, Chronic |
Human Genome Sciences Inc. |
2005-05 | PHASE2 |
| NCT00266318 | COMPLETED | Hepatitis C |
Beth Israel Medical Center |
2005-12 | PHASE4 |
| NCT00656006 | COMPLETED | Chronic Hepatitis C |
Human Genome Sciences Inc. |
2005-11 | PHASE2 |
| NCT00279565 | TERMINATED | Hepatitis C, Chronic |
Indivior Inc. |
2005-08 | PHASE4 |
| NCT00142103 | COMPLETED | Hepatitis, Chronic Active |
Pfizer |
2005-09 | PHASE1 |
| NCT00948220 | COMPLETED | Hepatitis C, Chronic; Liver Diseases; Virus Diseases |
University of Ulm |
2003-07 | PHASE4 |
| NCT00128271 | COMPLETED | Hepatitis C |
Peregrine Pharmaceuticals |
2005-08 | PHASE1 |
| NCT00475072 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2003-06 | PHASE4 |
| NCT00502788 | COMPLETED | Hepatitis C; Thalassemia |
Carelon Research |
2003-05 | PHASE2 |
| NCT00093093 | COMPLETED | Chronic Hepatitis C |
Bausch Health Americas, Inc. |
2004-06 | PHASE3 |
| NCT00381953 | COMPLETED | Hepatitis C |
Foundation for Liver Research |
2003-02 | PHASE3 |
| NCT00087568 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2003-01 | PHASE4 |
| NCT01120795 | COMPLETED | Chronic Hepatitis C |
Melbourne Health |
2004-02 | PHASE4 |
| NCT00077649 | COMPLETED | Hepatitis C, Chronic |
Hoffmann-La Roche |
2004-01 | PHASE4 |
| NCT00211848 | COMPLETED | Hepatitis C |
Icahn School of Medicine at Mount Sinai |
2000-06 | PHASE2 |
| NCT00249860 | COMPLETED | Hepatitis C |
EMD Serono |
2002-09 | PHASE3 |
| NCT00059358 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-09 | PHASE1; PHASE2 |
| NCT00835536 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2003-09 | PHASE1 |
| NCT00835146 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2003-09 | PHASE1 |
| NCT00959933 | COMPLETED | Chronic Hepatitis C |
Sandoz |
2001-04 | PHASE1 |
| NCT01913964 | COMPLETED | Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis; Fatigue in Workers With Chronic C Hepatitis; Fatigue |
University of Catania |
1997-10 | PHASE4 |
| NCT00215839 | UNKNOWN | Chronic Hepatitis C Infection in HIV Infected Persons; HIV Infections |
Hepatitis Resource Network |
PHASE3 | |
| NCT00215865 | COMPLETED | Chronic Hepatitis C Virus Infection |
Hepatitis Resource Network |
PHASE3 | |
| NCT00546442 | COMPLETED | Chronic Hepatitis C |
Valme University Hospital |
2006-05 | PHASE4 |
| NCT00127777 | UNKNOWN | Hepatitis C, Chronic |
University Hospital, Saarland |
2002-07 | PHASE4 |
| NCT00466219 | COMPLETED | Hepatitis C |
University Hospital, Geneva |
2002-05 | PHASE3 |
| NCT00084279 | COMPLETED | Chronic Hepatitis C |
InterMune |
2004-04 | PHASE2 |
| NCT00120861 | COMPLETED | Chronic Hepatitis C |
Merck Sharp & Dohme LLC |
2005-01 | PHASE2 |
| NCT00001015 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00275938 | COMPLETED | Chronic Hepatitis B |
National Taiwan University Hospital |
1998-10 | PHASE2; PHASE3 |
| NCT00315432 | COMPLETED | Hepatitis C; HIV; Anemia |
Ortho Biotech Products, L.P. |
2000-09 | PHASE2 |
| NCT00097045 | COMPLETED | Hepatitis C |
Intarcia Therapeutics |
2004-11 | PHASE2 |
| NCT00001123 | COMPLETED | Hantavirus Pulmonary Syndrome |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00154869 | UNKNOWN | Hepatitis B, Chronic; Hepatitis C, Chronic |
National Taiwan University Hospital |
2004-06 | PHASE3 |
| NCT00370617 | UNKNOWN | Chronic Hepatitis C; Insulin Resistance |
University of Turin, Italy |
2006-09 | PHASE4 |
| NCT00196664 | COMPLETED | Chronic Hepatitis C |
French National Agency for Research on AIDS and Viral Hepatitis |
2005-10 | PHASE3 |
| NCT00000699 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00008463 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
2000-11 | PHASE2 |
| NCT00055341 | COMPLETED | HIV Infections; Hepatitis C; Hemophilia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2002-03 | PHASE2 |
| NCT00146016 | COMPLETED | Chronic Hepatitis C |
UMC Utrecht |
2000-02 | PHASE3 |
| NCT00196586 | COMPLETED | HIV Infections; Chronic Hepatitis C |
French National Agency for Research on AIDS and Viral Hepatitis |
2003-04 | PHASE2 |
| NCT00143000 | COMPLETED | Hepatitis C Virus |
NORDynamIC Study Group |
2004-04 | PHASE4 |
| NCT00909129 | COMPLETED | Human Immunodeficiency Virus; Chronic Hepatitis C |
Karolinska Institutet |
||
| NCT00001729 | COMPLETED | Chronic Hepatitis C; Fibrosis; Hemolytic Anemia |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
1997-10 | PHASE3 |
| NCT00002298 | TERMINATED | HIV Infections |
ICN Pharmaceuticals |
||
| NCT00000833 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00215891 | COMPLETED | Chronic Hepatitis C Infection in HIV-Infected Persons; HIV Infections |
Hepatitis Resource Network |
PHASE3 | |
| NCT00239252 | COMPLETED | Hepatitis C |
Astellas Pharma Inc |
PHASE3 | |
| NCT00088504 | COMPLETED | Hepatitis C; Hepatitis |
Vertex Pharmaceuticals Incorporated |
2004-07 | PHASE2 |
| NCT00299936 | COMPLETED | Chronic Hepatitis C |
Weill Medical College of Cornell University |
PHASE3 | |
| NCT00122629 | TERMINATED | Hepatitis C, Chronic |
French National Agency for Research on AIDS and Viral Hepatitis |
2000-10 | PHASE3 |
| NCT00383864 | COMPLETED | Hepatitis C |
Hospital Clinic of Barcelona |
2001-07 | PHASE4 |
| NCT00274495 | TERMINATED | Chronic Hepatitis C Infection; Fatty Liver |
Beth Israel Medical Center |
2006-01 | PHASE4 |
| NCT00117533 | UNKNOWN | Chronic Hepatitis B; Chronic Hepatitis D |
National Taiwan University Hospital |
2005-09 | PHASE4 |
| NCT00000772 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-06)
Check the
Ribavirin (ICN-1229)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Ribavirin (ICN-1229) Solubility in DMSO
- Ribavirin (ICN-1229) Stock Solution
- Ribavirin (ICN-1229) Storage
- Ribavirin (ICN-1229) Stability
- Ribavirin (ICN-1229) Molecular Weight
- Ribavirin (ICN-1229) SMILES
- Ribavirin (ICN-1229) CAS Number
- Ribavirin (ICN-1229) Chemical Structure (2D and 3D)
- Ribavirin (ICN-1229) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.